Keep updated with the latest MDPP news via our newsletter.
The Biomedical Translation Bridge (BTB) program came to a close in August with a BTB Finale which celebrated the success of all of the funded BTB projects. The BTB Program was launched in May 2019 and the MDPP were a key partner working with MTPConnect in delivery of the program. Dr Andrew Milligan, MDPP's MedTech Venture Partner for the BTB program, chaired a session at the finale and Prof Karen Reynolds was involved in a panel discussion.
Some highlights of the BTB Program are:
Dr Andrew Milligan (pictured below) is now taking a similar role as MDPP's MedTech Venture Partner for the Clinical Translation and Commercialisation Medtech (CTCM) Program, delivered by MTPConnect.
Hindsight is great – but foresight is better!Researchers and innovators are invited to attend a workshop hosted by Michael Masterson, Managing Director at global intangible asset advisory and valuation firm EverEdge Global.
Date: Wednesday 24 August 2022
Time: 12pm - 1pm
Location: Flinders University
182 Victoria Square
Adelaide SA 5000
RSVP: Click here to register.
We look forward to seeing you there!:
Join us for MDPP's annual showcase event (featuring the BridgeTech Program and Adelaide Intermediary Program)
We look forward to welcoming friends and colleagues back to an in-person celebration of South Australian medtech!
We hope to have many MDPP alumni present on the night and lots of examples of South Australia's burgeoning medtech sector!
Tuesday 28 June
5.30pm - 7.30pm ACST
Registration open from 5pm for a 5:30pm start
Stone & Chalk
North Terrace, Adelaide SA 5000
Drinks and canapes will be provided.
Dr Chris Wilkinson from Madderns Patent & Trademark Attorneys will be holding a series of lunchtime seminars on Intellectual Property (IP) from June to August at the Flinders Tonsley Campus.
The seminars will be held at Tonsley, and livestreamed for those unable to attend, and will cover:
June 7th (12pm) - Overview of the different types of IP; Tangible benefits of IP to SMEs from several large economic studies;
July 5th (11am) - How is the validity of a patent assessed (novelty, inventive Step, subject matter, support/utility); Inventors and owners;
August 2nd (11am) - Patent searching, and assessing freedom to operate (and infringement); the international patenting process;
August 30th (11am) - Trademarks, trade secrets, and designs.
There will be time at the end of each session for attendees to ask any questions they have on IP
Chris has extensive experience helping local and international clients to protect their IP in Australia and abroad. He is a Registered Australian and New Zealand Patent and Trademark attorney and a partner at Madderns Patent and Trademark Attorneys. He has over 16 years experience working in IP, and draws upon his technical expertise gained from a PhD in high energy astrophysics, and postdoctoral positions in defence (explosive effects) and medical research (bioinformatics) to assist clients in a range of technical areas including AI/ML, healthcare, communications and space. Chris is also a Trustee with LESANZ, a professional society focussed on supporting innovation in AU and NZ.
Don’t miss this opportunity to hear from an experienced Patent Attorney and ask any questions you have on IP.
Please register via Eventbrite if you would like to attend in person or via the livestream
If you would like to watch the earlier sessions please visit the IP Seminar page.
MTPConnect has launched a new program with industry partners supporting early clinical development of medical devices. The Clinical Translation and Commercialisation - Medtech (CTCM) program is a $19.75 million initiative funded by the Federal Government’s Medical Research Future Fund and will offer financial assistance, educational support and infrastructure access to Australian small to medium-sized enterprises (SMEs).
The Medical Device Partnering Program (led by Flinders University) is proud to be announced as a partner on the program. The other partners are the Medical Technology Association of Australia, Cicada Innovations, the BridgeTech Program and Therapeutic Innovation Australia.
MDPP Director Professor Karen Reynolds said: “MDPP has a 13-year track record of supporting medical device ventures across the innovation life cycle, from ideation to product development to commercialisation. We’re delighted to now join MTPConnect and other partners to deliver the new CTCM program, leveraging our capabilities and extensive networks to assist Australian SMEs achieve key clinical milestones and accelerate the adoption and commercialisation of new devices.”
Further information about the CTCM Program - including guidelines, details about eligibility and how to apply - is available on the MTPConnect website
The Australia-China Centre for Personal Health Technologies is a collaborative research Centre led by Flinders University in Australia and Nankai University in China.
The final personal health symposium for the year will be hosted by La Trobe University. The symposium showcases leading experts in the Personal Health Technologies arena from China and Australia.
1. Nano-liquid Biopsy: New Strategy towards Cancer Diagnosis and Treatment Response. A/Prof Yuling Wang, Macquarie University
2. Development of red-to-NIR emissive radical cations and their bio-imaging applications. A/Prof Meng Gao, South China University of Technology
3. Saliva “omics” to identify biomarkers of Alzheimer’s disease. A/Prof Wayne Leifert, CSIRO
4. Small-Molecule AIE Luminogens for In Vitro Diagnostics. Dr. Bo Situ, Nanfang Hospital, Southern Medical University
5. Industrialisation of a novel biosensor for non-invasive bladder cancer diagnostic. A/Prof Melanie Macgregor, Flinders University
6. Background-free luminescence bioassay and imaging using long lifetime responsive probes. Dr. Run Zhang, The University of Queensland
7. Towards Effective Targeted Immunization with Influence Maximization Models. A/Prof Chong Di, Shandong Artificial Intelligence Institute, Qilu University of Technology
8. Synthesis and biomedical application of multifunctional nanoprobes with aggregation-induced emission characteristics. Dr. Hanlin Ou, Nankai University
This project received grant funding from the Australian Government as part of the Australia-China Science and Research Fund program and the Ministry of Science and Technology of the People’s Republic of China.
Weblink for further information about our centre:
Information provided by Phillips Ormonde Fitzpatrick
The Federal government will launch a patent box scheme targeted at the medical and biotechnology sector. The scheme, to apply from 1 July 2022, is aimed to further encourage the commercialisation of medical and biotechnology innovations in Australia.
Under the patent box, income derived from eligible patents will be taxed at a concessional rate of 17%, a reduction of 8% for SMEs and 13% for large businesses. At this stage, the scheme will apply to income derived from Australian-owned and developed medical and biotechnology patents applied for after 11 May 2021.
The aim of the patent box is to encourage businesses to retain or locate the development, manufacture and exploitation of patents to their innovations in Australia.
Patent box schemes are already in place in many European countries and the innovation sector has advocated for a similar scheme in Australia for many years on the basis that it is vital to attract companies to invest and maintain that investment in Australia. The government has indicated that it will follow the OECD’s guidelines on patent boxes to ensure it meets internationally accepted standards.
A consultation process with industry will occur prior to the July 2022 launch. Initial submissions to the Discussion Paper on Policy Design closed on 16 August 2021.Therefore, precise details of the scheme will not be known until submissions have been considered. For the patent box to be of value, key considerations must take into account the definition of an eligible patent, the definition of a medical or biotechnology patent, whether costs associated with conducting R&D and various clinical trials outside of Australia apply, and whether patents held by companies located elsewhere, but where an Australian based company has an exclusive licence to exploit the patent, can access the scheme.
We will keep you updated on developments as details become known.
Scott Whitmore PhD
Phillips Ormonde Fitzpatrick
08 8224 9901
Click here for the full article